Video

Thoracic oncologist Dr Joshua Sabari is joining us from WCLC 2026 in Seoul to report on the latest data and share his expert perspectives on the most recent advances in HER2-mutant non-small cell lung cancer (NSCLC).   

 

Dr Sabari is expected to share insights on the following studies: 

 

  • DESTINY-Lung04: First-line trastuzumab deruxtecan in patients with metastatic HER2-mutant NSCLC (Primary Results) 
    Rotow J, et al. PL03.08, WCLC 2026 
  • SOHO-01: Molecular landscape of acquired resistance to sevabertinib in HER2-mutant NSCLC (Exploratory Biomarker Analysis)  
    Le X, et al. MO12.04, WCLC 2026 
  • Beamion LUNG-1: Acquired resistance to zongertinib treatment in patients with HER2-mutant NSCLC (Phase 1b Study) 
    Planchard D, et al. MO12.05, WCLC 2026 

 

Will new data impact clinical practice? Come back soon to find out.

 

See more lung cancer data from recent conferences: Catch up on Highlights from ASCO 2026 and Oncogene-addicted NSCLC highlights from ELCC 2026 on the right of this page, or scroll up to 'Summary and next episodes' if you're on mobile.

 

  • Understand the clinical trial data and emerging profiles of therapies for the treatment of molecularly driven lung cancer, including treatments for HER2-directed NSCLC 

Dr Sabari grew up in Brooklyn, New York and was interested in science and problem solving from an early age. As a child, he loved taking things apart so he could figure out how they worked. During his undergraduate education, he majored in philosophy where he studied ethics and shared decision making. It was this same passion, partnered with his compassion for others, that inspired him to attend medical school and ultimately choose the specialty of oncology.

 

At NYU Langone’s Perlmutter Cancer Center, he specialises in caring for people who have lung cancers, including non-small cell lung cancer and small cell lung cancer. Dr Sabari understands that a cancer diagnosis is frightening, and navigating treatment can be overwhelming.  Dr Sabari believes that every person should be treated as an individual and receive personalised treatment and care. His goal is to help guide patients and their families through treatment, so they feel comfortable, supported, and confident in their care.

 

Dr Sabari works closely with a team of cancer specialists to deliver advanced treatments with a compassionate and patient-centred focus. Together, they strive to fight cancer and minimise its physical symptoms, so everyone under their care can spend their lives doing what matters most to them.

 

Dr Sabari’s research focuses on developing new treatments for people with lung cancers. His goal is to develop biomarker-driven clinical trials that offer patients unprecedented access to novel therapies and personalised treatments. Dr Sabari aims to better understand why people develop cancer and wishes to create innovative ways to harness the body’s immune system to fight cancer.

Dr Joshua Sabari has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Abbvie, AstraZeneca, EMD Serono, Genentech, Janssen, Jazz, Loxo Lilly, Mirati/BMS, Pfizer, Regeneron, Revolution Medicines, Sanofi Genzyme, Takeda

Thoracic oncologist Dr Joshua Sabari is joining us from WCLC 2026 in Seoul to report on the latest data and share his expert perspectives on the most recent advances in HER2-mutant non-small cell lung cancer (NSCLC).   

 

Dr Sabari is expected to share insights on the following studies: 

 

  • DESTINY-Lung04: First-line trastuzumab deruxtecan in patients with metastatic HER2-mutant NSCLC (Primary Results) 
    Rotow J, et al. PL03.08, WCLC 2026 
  • SOHO-01: Molecular landscape of acquired resistance to sevabertinib in HER2-mutant NSCLC (Exploratory Biomarker Analysis)  
    Le X, et al. MO12.04, WCLC 2026 
  • Beamion LUNG-1: Acquired resistance to zongertinib treatment in patients with HER2-mutant NSCLC (Phase 1b Study) 
    Planchard D, et al. MO12.05, WCLC 2026 

 

Will new data impact clinical practice? Come back soon to find out.

 

See more lung cancer data from recent conferences: Catch up on Highlights from ASCO 2026 and Oncogene-addicted NSCLC highlights from ELCC 2026 on the right of this page, or scroll up to 'Summary and next episodes' if you're on mobile.

  • Understand the clinical trial data and emerging profiles of therapies for the treatment of molecularly driven lung cancer, including treatments for HER2-directed NSCLC 

Dr Sabari grew up in Brooklyn, New York and was interested in science and problem solving from an early age. As a child, he loved taking things apart so he could figure out how they worked. During his undergraduate education, he majored in philosophy where he studied ethics and shared decision making. It was this same passion, partnered with his compassion for others, that inspired him to attend medical school and ultimately choose the specialty of oncology.

 

At NYU Langone’s Perlmutter Cancer Center, he specialises in caring for people who have lung cancers, including non-small cell lung cancer and small cell lung cancer. Dr Sabari understands that a cancer diagnosis is frightening, and navigating treatment can be overwhelming.  Dr Sabari believes that every person should be treated as an individual and receive personalised treatment and care. His goal is to help guide patients and their families through treatment, so they feel comfortable, supported, and confident in their care.

 

Dr Sabari works closely with a team of cancer specialists to deliver advanced treatments with a compassionate and patient-centred focus. Together, they strive to fight cancer and minimise its physical symptoms, so everyone under their care can spend their lives doing what matters most to them.

 

Dr Sabari’s research focuses on developing new treatments for people with lung cancers. His goal is to develop biomarker-driven clinical trials that offer patients unprecedented access to novel therapies and personalised treatments. Dr Sabari aims to better understand why people develop cancer and wishes to create innovative ways to harness the body’s immune system to fight cancer.

Dr Joshua Sabari has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Abbvie, AstraZeneca, EMD Serono, Genentech, Janssen, Jazz, Loxo Lilly, Mirati/BMS, Pfizer, Regeneron, Revolution Medicines, Sanofi Genzyme, Takeda

Programme summary
  • clock Duration 3 MIN
  • clock Language(s) flag
Other episodes of this series
Highlights from ASCO 2026

Highlights from ASCO 2026

Expert insights on the latest data

Oncogene-addicted NSCLC highlights from ELCC 2026

Oncogene-addicted NSCLC highlights from ELCC 2026

Expert insights on the latest NSCLC data

<i>HER2</i>-mutant NSCLC: Evolving evidence, changing practice

HER2-mutant NSCLC: Evolving evidence, changing practice

Coming soon! Insights on the latest WCLC 2026 data

Current Episode
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer.
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
LUNG CONNECT

LUNG CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Pierre Fabre Laboratories, Boehringer Ingelheim and AstraZeneca.

Meet the experts
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories, Thermo Fisher Scientific and Daiichi Sankyo.

Meet the experts Independent IME approved
Programme summary
  • clock Duration MIN
  • clock Language(s) flag
Other episodes of this series
Highlights from ASCO 2026

Highlights from ASCO 2026

Expert insights on the latest data

Oncogene-addicted NSCLC highlights from ELCC 2026

Oncogene-addicted NSCLC highlights from ELCC 2026

Expert insights on the latest NSCLC data

<i>HER2</i>-mutant NSCLC: Evolving evidence, changing practice

HER2-mutant NSCLC: Evolving evidence, changing practice

Coming soon! Insights on the latest WCLC 2026 data

Current Episode
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer.
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
LUNG CONNECT

LUNG CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Pierre Fabre Laboratories, Boehringer Ingelheim and AstraZeneca.

Meet the experts
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories, Thermo Fisher Scientific and Daiichi Sankyo.

Meet the experts Independent IME approved

Other programmes of interest

blueprint BluePrintInfographic / Flashcard
Oncology 
Biomarker testing in non-small cell lung cancer (NSCLC)

Insights from patients and caregivers

Experts
Prof. Christian Rolfo, Prof. Fernando López-Ríos, Dr Rodrigo Paredes de la Fuente, Anne-Marie Baird, Amy C. Moore, Shani Shilo
Endorsed by
LUNGevity The Israeli Lung Cancer Foundation
Biomarker Collaborative NTRKers Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jul 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.
micro-learning Micro learning - Video, slides and more
Oncology 
The evolving treatment landscape in HER2-mutant NSCLC

Expert insights on how the latest evidence is shaping clinical practice

Experts
Dr Devika Das, Dr Tom Newsom-Davis
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jul 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer
animated-video Animated Video
Oncology 
The critical role of testing and management in NTRK-positive non-small cell lung cancer (NSCLC)

Using molecular testing to enable personalised care

Experts
Dr Herbert Loong
Endorsed by
ICAN international cancer advocacy network ISLB NTRKers
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.
symposium Masterclass / Symposium
Oncology 
ER+/HER2- metastatic breast cancer: ESMO Breast Cancer 2026 Satellite Symposium highlights

Experts discuss 2nd line+ treatment strategies in endocrine therapy-eligible patients

Experts
Prof. Nadia Harbeck, Dr Tiffany Traina, Prof. Frederik Marmé
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Jun 2026

This programme has been sponsored by Menarini Stemline and is intended for HCPs only.
conference-update Conference update

Episode

1

of 3

episode
Oncology 
Highlights from ASCO 2026

Expert insights on the latest data

Experts
Dr Herbert Loong, Dr Isabel Preeshagul, Prof. Mark Socinski, Prof. Evan Yu, Prof. Hans Prenen, Dr Paolo Tarantino
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jun 2026
  • Non-accredited Independent Medical Education